ストックスクリーナーアプリを入手
3.77
2.08%
-0.08
アフターアワーズ：
3.77
Maxcyte Inc (MXCT) 最新ニュース
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
263,833 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by Rice Hall James & Associates LLC - MarketBeat
MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks
BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks
Bio Buyout: MaxCyte Acquires SeQure - Law Street Media
BlackRock Adjusts Holdings in MaxCyte, Inc. - TipRanks
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform - News-Medical.Net
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
MaxCyte and TG Therapeutics partner on next-gen cell therapy for MS - DirectorsTalk Interviews
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell ... - The Bakersfield Californian
Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan
Boston-area diagnostics startup scooped up by Maryland company - The Business Journals
Rockville biotech MaxCyte snaps up Boston-area diagnostics startup SeQure Dx - The Business Journals
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - MSN
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference - The Manila Times
MaxCyte, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Release Date and Earnings Call Details - Nasdaq
MaxCyte to Announce 2024 Financial Results and Engage in Key Investor Conference - TipRanks
MaxCyte's Critical Q4 Earnings & Strategic Healthcare Conference Appearance: Key Dates Revealed - StockTitan
BlackRock, Inc. Reduces Stake in MaxCyte Inc: An In-Depth Analys - GuruFocus.com
MaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by Gagnon Securities LLC - MarketBeat
MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks
MaxCyte Expands Stock Capital with New Common Stock Issuance - TipRanks
MaxCyte Announces Executive Stock Transaction - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
ConnectOne Bancorp (CNOB) Issues Press Release on Acquisition of SeQure Dx by MaxCyte - Defense World
MaxCyte, Inc. Acquires SeQure DX Inc. to Enhance Cell Engineering Offerings - Defense World
MaxCyte director exercises options, sells shares By Investing.com - Investing.com Nigeria
MaxCyte director exercises options, sells shares - MSN
MaxCyte Acquires SeQure Dx - FinSMEs
MaxCyte Buys SeQure Dx for Up to $7M - USA Herald
MaxCyte announces acquisition of SeQure Dx - ShareCast
Market news - Research the market
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) -January 30, 2025 at 10:37 am EST - Marketscreener.com
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) - Business Wire
Cell Engineering Biz MaxCyte Buys Gene Firm For Up To $7M - Law360
MaxCyte buys gene therapy analytics firm SeQure Dx -January 30, 2025 at 08:56 am EST - Marketscreener.com
MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion - TipRanks
Cell Engineering Group MaxCyte Buys US-based SeQure Dx -January 30, 2025 at 05:05 am EST - Marketscreener.com
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx -January 30, 2025 at 04:25 am EST - Marketscreener.com
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - The Manila Times
MaxCyte Expands Cell Engineering Capabilities with Acquisition of SeQure Dx - TipRanks
MaxCyte, Inc. Acquires SeQure Dx to Enhance Cell and Gene Therapy Solutions - Nasdaq
1.10%
0.57%
大文字化:
|
ボリューム (24 時間):